Herhangi bir kurum tarafından destek almamıştır.
The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.
| Primary Language | English |
|---|---|
| Subjects | Emergency Medicine |
| Journal Section | Review |
| Authors | |
| Submission Date | May 1, 2022 |
| Acceptance Date | November 6, 2022 |
| Publication Date | December 30, 2022 |
| DOI | https://doi.org/10.55994/ejcc.1112050 |
| IZ | https://izlik.org/JA98YJ99RR |
| Published in Issue | Year 2022 Volume: 4 Issue: 3 |